PF-04531083

PF‑04531083 is a small molecule investigational drug developed by Pfizer as a selective blocker of the voltage-gated sodium channel Nav1.8 (Sodium channel protein type X alpha subunit). It was designed to treat pain conditions, including chronic pain and postoperative pain, by inhibiting Nav1.8 channels involved in nociceptive signaling. The compound is orally bioavailable and can cross the blood-brain barrier. Clinical development reached phase II trials for indications such as chronic pain and postoperative dental pain, but all programs were discontinued[1][2][4][5][7]. Preclinical studies also explored its potential in neuropathic/inflammatory pain and central nervous system disorders[3][6].

Other names

N-(6-Amino-5-(2-chloro-5-methoxyphenyl)pyridin-2-yl)-1-methyl-1H-pyrazole-5-carboxamide1079400-07-9MFCD28411617MFCD-28411617MFCD 28411617